knowledge -WSS

knowledge

author：fashion 2025-09-29 04:23:16 - browse：656

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Medicare wants to send $9 billion to 340B hospitals

WSS

Dozens of beaches across Northeast closed for swimming due to high levels of bacteria in water

Why the Crimean Bridge is key to Russia's war in Ukraine

Presidential fundraising highlights so far: Trump brings in more than DeSantis

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

Presidential fundraising highlights so far: Trump brings in more than DeSantis

entertainment

knowledge

focus

Jerome Adams on the need for new antivirals for Covid

Create a giant ice tray with this foil pan hack to keep food cold this summer

Continuity nursing helped my family in our darkest PICU moments

ACA's risk program benefits Blue Cross Blue Shield insurers

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Trump demands the U.S. pay no more for drugs than other countries … again

DOJ, FTC to increase scrutiny of all types of health care mergers

Affirmative action in medical school literally saved lives

Teachers share how revamped forgiveness program helped with their student loans

hotspot

Eisai exec who led development of Alzheimer’s drug to retire

Stanford president to resign after investigation of research

The kidney, in all its complexity, is captured in a new atlas

Norman Reedus' Daryl Dixon

Biden’s NIH nominee is languishing in Congress

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

hotspot

knowledge

focus

leisure time